Starpharma Holdings Limited
(ASX:SPL) has signed a Memorandum of Understanding with a Chinese company who is a major provider of condoms to the Chinese government.
The MOU outlines the key commercial and other terms for Starpharma’s partner to manufacture and sell a VivaGel coated condom to the government segment of the Chinese market.
Starpharma will now work with its partner to proceed with the regulatory process in preparation for market launch.
Starpharma CEO Dr Jackie Fairley said that partnering with a local Chinese company has the potential to facilitate entry into a market not captured by its current licenses.
Starpharma recorded a net loss of $18.95 million at 30 June 2015.
